title: [Effect of dangua recipe on glycolipid metabolism and VCAM-1 and its mRNA expression level in Apo E(-/-) mice with diabetes mellitus].
abstract: OBJECTIVE
  To study the effect of Dangua Recipe (DGR) on glycolipid metabolism, vascular cell adhesion molecule-1 (VCAM-1) and its mRNA expression level of transgenic Apo E(-/-) mouse with spontaneous atherosclerosis, thus revealing its partial mechanism for curing diabetes mellitus (DM) with angiopathy.
  
  
  METHODS
  Diabetic model was prepared by peritoneally injecting streptozotocin (STZ) to Apo E(-/-) mouse. Totally 32 modeled mice were stratified by body weight, and then divided into 4 groups referring to blood glucose levels from low to high by random digit table, i.e., the model group (MOD, fed with sterile water, at the daily dose of 15 mL/kg), the DGR group (fed with DGR at the daily dose of 15 mL/kg), the combination group (COM, fed with DGR at the daily dose of 15 mL/kg and pioglitazone at the daily dose of 4.3 mg/kg), and the pioglitazone group (PIO, at the daily dose of 4.3 mg/kg), 8 in each group. Another 8 normal glucose C57 mouse of the same age and strain were recruited as the control group. All interventions lasted for 12 weeks by gastrogavage. The fasting blood glucose (FBG), body weight, food intake, water intake, skin temperature, the length of tail, and the degree of fatty liver were monitored. The hemoglobin A1c (HbA1c), total cholesterol (TC), and LDL-C were determined. Endothelin-1 (ET-1) was determined by radioimmunoassay. Nitrogen monoxidum (NO) was determined by nitrate reductase. The kidney tissue VCAM-1 level was analyzed with ELISA. The expression of VCAM-1 mRNA in the kidney tissue was detected with real time quantitative PCR.
  
  
  RESULTS
  Compared with the control group, the body weight and food intake decreased, water intake increased in all the other model groups (P < 0.05). Besides, the curve of blood glucose was higher in all the other model groups than in the control group (P < 0.01). Compared with the model group, the body weight increased; levels of HbAlc, TC, LDL-C, ET-1, and VCAM-1 were significantly lower; and skin temperature was higher in the DGR group (P < 0.05, P < 0.01). Compared with the PIO group, body weight, the increment of body weight, FBG, TC, and LDL-C were lower (P < 0.05, P < 0.01); food intake and water intake increased more and the tail length was longer in the DRG group (P < 0.01). There was no statistical difference in the level of NO among groups. The degree of fatty liver in the model group was significantly severer than that in the control group (P < 0.05). It was obviously alleviated in the DGR group (P < 0.05) when compared with the model group and the PIO group (P < 0.05, P < 0.01). But it was severer in the PIO group than in the model group (P < 0.01). The degree of fatty liver in the combination group ranged between that of the DGR group and the PIO group (P < 0.05). The level of VCAM-1 mRNA expression was significantly lower in the DGR group than in the model group, the PIO group, and the combination group (P < 0.05).
  
  
  CONCLUSIONS
  DGR had effect in lowering blood glucose and blood lipids, and fighting against fatty liver of transgenic Apo E(-/-) mouse with spontaneous atherosclerosis. DGR played an effective role in preventing and treating DM with angiopathy by comprehensively regulating glycolipid metabolism and promoting the vascular function.
authors.forename: Xian-Pei
authors.initials: XP
authors.lastname: Heng
authors.forename: Liang
authors.initials: L
authors.lastname: Li
authors.forename: Su-Ping
authors.initials: SP
authors.lastname: Huang
authors.forename: Yan
authors.initials: Y
authors.lastname: Chen
authors.forename: Miao-Xian
authors.initials: MX
authors.lastname: Lin
authors.forename: Huai-Shan
authors.initials: HS
authors.lastname: Zhuang
authors.forename: Qun-Fang
authors.initials: QF
authors.lastname: Yan
authors.forename: Liu-Qing
authors.initials: LQ
authors.lastname: Yang
authors.forename: Ling
authors.initials: L
authors.lastname: Chen
authors.forename: Qing
authors.initials: Q
authors.lastname: Lin
authors.forename: Xin-Ling
authors.initials: XL
authors.lastname: Cheng
authors.forename: Min-Ling
authors.initials: ML
authors.lastname: Chen
authors.forename: Yi-Chu
authors.initials: YC
authors.lastname: Chen
authors.forename: Yuan-Long
authors.initials: YL
authors.lastname: Lan
authors.forename: Zhi-Ta
authors.initials: ZT
authors.lastname: Wang
authors.forename: Shu-Hong
authors.initials: SH
authors.lastname: Yao
authors.forename: Zhi-San
authors.initials: ZS
authors.lastname: Zhang
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000188:drug therapy; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D000077205:Pioglitazone; D012333:RNA, Messenger / Q000235:genetics; D011897:Random Allocation; D045162:Thiazolidinediones / Q000494:pharmacology; D019010:Vascular Cell Adhesion Molecule-1 / Q000235:genetics / Q000378:metabolism*
chemical_list: D001057:Apolipoproteins E; D001786:Blood Glucose; D004365:Drugs, Chinese Herbal; D008055:Lipids; D012333:RNA, Messenger; D045162:Thiazolidinediones; D019010:Vascular Cell Adhesion Molecule-1; D000077205:Pioglitazone